Immunocore Financial Statements From 2010 to 2024

IMCR Stock  USD 32.28  0.16  0.50%   
Immunocore Holdings financial statements provide useful quarterly and yearly information to potential Immunocore Holdings investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Immunocore Holdings financial statements helps investors assess Immunocore Holdings' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Immunocore Holdings' valuation are summarized below:
Gross Profit
54.1 M
Profit Margin
(0.16)
Market Capitalization
1.6 B
Enterprise Value Revenue
4.0324
Revenue
296.3 M
There are over one hundred nineteen available fundamental trends for Immunocore Holdings, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to confirm Immunocore Holdings' regular fundamental performance against the performance between 2010 and 2024 to make sure the trends are evolving in the right direction. As of 11/25/2024, Market Cap is likely to grow to about 3.5 B. Also, Enterprise Value is likely to grow to about 3.1 B

Immunocore Holdings Total Revenue

261.9 Million

Check Immunocore Holdings financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunocore Holdings' main balance sheet or income statement drivers, such as Interest Expense of 3.6 M, Other Operating Expenses of 324.5 M or Tax Provision of 2.5 M, as well as many indicators such as Price To Sales Ratio of 12.72, Dividend Yield of 0.0 or PTB Ratio of 8.6. Immunocore financial statements analysis is a perfect complement when working with Immunocore Holdings Valuation or Volatility modules.
  
Check out the analysis of Immunocore Holdings Correlation against competitors.
To learn how to invest in Immunocore Stock, please use our How to Invest in Immunocore Holdings guide.

Immunocore Holdings Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Other Current Liabilities120 M114.3 M35.5 M
Slightly volatile
Total Current Liabilities72 M139 M48.5 M
Slightly volatile
Other Liabilities5.1 M5.3 M22.4 M
Pretty Stable
Net Tangible Assets336.1 M320.1 M172.7 M
Slightly volatile
Accounts Payable11.5 M17.8 M7.6 M
Slightly volatile
Other Assets7.5 M10.4 M6.3 M
Slightly volatile
Net Receivables33.1 M61.4 M22.7 M
Slightly volatile
Other Stockholder Equity1.2 B1.1 B302.1 M
Slightly volatile
Total Current Assets270.4 M528.8 M225.6 M
Slightly volatile
Property Plant Equipment33.1 M36.4 M23.1 M
Slightly volatile
Other Current Assets9.2 M9.7 M9.8 M
Slightly volatile
Total Assets350.7 M597 M255.3 M
Slightly volatile
Short and Long Term Debt Total65.9 M84 M38.4 M
Slightly volatile
Total Stockholder Equity387.3 M368.8 M119.1 M
Slightly volatile
Property Plant And Equipment Net40.1 M42.7 M28.4 M
Slightly volatile
Cash245.9 M442.6 M172.1 M
Slightly volatile
Non Current Assets Total51.5 M68.2 M35.3 M
Slightly volatile
Long Term Debt39.7 M48 M27.2 M
Slightly volatile
Cash And Short Term Investments245.9 M442.6 M172.1 M
Slightly volatile
Common Stock Shares Outstanding41.2 M48.9 M32.3 M
Slightly volatile
Liabilities And Stockholders Equity350.7 M597 M255.3 M
Slightly volatile
Non Current Liabilities Total66 M89.1 M85.2 M
Slightly volatile
Total Liabilities177.3 M228.2 M150.5 M
Slightly volatile
Net Invested Capital210 M416.9 M130.6 M
Slightly volatile
Property Plant And Equipment Gross49.7 M95 M32.5 M
Slightly volatile
Net Working Capital212.6 M389.8 M156.3 M
Slightly volatile
Intangible Assets351369191 K
Slightly volatile
Current Deferred Revenue5.2 M5.5 M32.9 M
Slightly volatile
Short and Long Term Debt15.3 M17.2 M18.8 M
Slightly volatile
Common Stock Total Equity800900980
Slightly volatile
Common Stock88.3 K135 K28 K
Slightly volatile
Good Will327.7 K368.6 K401.4 K
Slightly volatile

Immunocore Holdings Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses324.5 M309.1 M91.1 M
Slightly volatile
Interest Income13.1 M12.5 M2.6 M
Slightly volatile
Depreciation And Amortization5.8 M4.1 M6.8 M
Pretty Stable
Selling General Administrative84.5 M154.9 M54.6 M
Slightly volatile
Selling And Marketing Expenses101 M115 M91.2 M
Slightly volatile
Total Revenue261.9 M249.4 M63.4 M
Slightly volatile
Research Development107.1 M163.5 M90.7 M
Slightly volatile
Total Operating Expenses189.6 M308 M144.4 M
Slightly volatile
Reconciled Depreciation5.8 M5.3 M6.9 M
Very volatile
Cost Of Revenue985.1 KM76.7 M
Slightly volatile

Immunocore Holdings Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Other Cashflows From Investing ActivitiesM2.1 M5.2 M
Pretty Stable
Depreciation5.3 M4.1 M5.2 M
Slightly volatile
Total Cash From Financing Activities32.6 M34.3 M53.7 M
Slightly volatile
End Period Cash Flow247.7 M442.6 M160.3 M
Slightly volatile
Stock Based Compensation23.1 M32.5 M10.3 M
Slightly volatile
Begin Period Cash Flow210.1 M402.5 M134.6 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio12.7213.39133.434
Slightly volatile
PTB Ratio8.69.055617.1415
Pretty Stable
Days Sales Outstanding85.4189.9008469
Slightly volatile
Book Value Per Share7.927.54453.102
Slightly volatile
Average Payables8.5 M11.1 M9.3 M
Slightly volatile
Stock Based Compensation To Revenue0.120.13020.1977
Slightly volatile
Capex To Depreciation1.391.32640.5848
Slightly volatile
PB Ratio8.69.055617.1415
Pretty Stable
EV To Sales11.3611.953429.8281
Slightly volatile
Payables Turnover0.05540.05835.3629
Slightly volatile
Sales General And Administrative To Revenue1.63.01.8335
Slightly volatile
Research And Ddevelopement To Revenue0.620.65572.8557
Slightly volatile
Capex To Revenue0.02070.02170.114
Slightly volatile
Cash Per Share9.519.05375.2815
Slightly volatile
Days Payables Outstanding6.6 K6.3 K1.7 K
Slightly volatile
Intangibles To Total Assets0.0010.00110.0221
Slightly volatile
Net Debt To EBITDA7.296.94332.2571
Slightly volatile
Current Ratio2.743.80393.3908
Very volatile
Tangible Book Value Per Share7.927.54453.045
Slightly volatile
Receivables Turnover7.884.063.6623
Slightly volatile
Graham Number9.2213.855211.1239
Very volatile
Shareholders Equity Per Share7.927.54453.102
Slightly volatile
Capex Per Share0.10.1110.1135
Slightly volatile
Revenue Per Share5.365.10191.5943
Slightly volatile
Price Book Value Ratio8.69.055617.1415
Pretty Stable
Days Of Payables Outstanding6.6 K6.3 K1.7 K
Slightly volatile
Ebt Per Ebit0.821.02080.9713
Slightly volatile
Effective Tax Rate0.130.0920.1581
Slightly volatile
Company Equity Multiplier1.541.61863.5835
Pretty Stable
Long Term Debt To Capitalization0.130.11520.2535
Pretty Stable
Quick Ratio2.923.77153.5759
Very volatile
Net Income Per E B T0.70.9080.8305
Pretty Stable
Cash Ratio2.243.18392.6077
Pretty Stable
Days Of Sales Outstanding85.4189.9008469
Slightly volatile
Price To Book Ratio8.69.055617.1415
Pretty Stable
Fixed Asset Turnover6.135.83661.9222
Slightly volatile
Price Sales Ratio12.7213.39133.434
Slightly volatile
Asset Turnover0.440.41780.1769
Slightly volatile
Price Fair Value8.69.055617.1415
Pretty Stable

Immunocore Holdings Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3.5 B3.3 B1.4 B
Slightly volatile
Enterprise Value3.1 BB1.2 B
Slightly volatile

Immunocore Fundamental Market Drivers

Cash And Short Term Investments442.6 M

Immunocore Upcoming Events

6th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Immunocore Holdings Financial Statements

Immunocore Holdings shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Immunocore Holdings investors may analyze each financial statement separately, they are all interrelated. The changes in Immunocore Holdings' assets and liabilities, for example, are also reflected in the revenues and expenses on on Immunocore Holdings' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue5.5 M5.2 M
Total Revenue249.4 M261.9 M
Cost Of RevenueM985.1 K
Stock Based Compensation To Revenue 0.13  0.12 
Sales General And Administrative To Revenue 3.00  1.60 
Research And Ddevelopement To Revenue 0.66  0.62 
Capex To Revenue 0.02  0.02 
Revenue Per Share 5.10  5.36 
Ebit Per Revenue(0.24)(0.25)

Pair Trading with Immunocore Holdings

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Immunocore Holdings position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immunocore Holdings will appreciate offsetting losses from the drop in the long position's value.

Moving against Immunocore Stock

  0.35KZR Kezar Life SciencesPairCorr
The ability to find closely correlated positions to Immunocore Holdings could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Immunocore Holdings when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Immunocore Holdings - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Immunocore Holdings to buy it.
The correlation of Immunocore Holdings is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Immunocore Holdings moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Immunocore Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Immunocore Holdings can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Immunocore Stock Analysis

When running Immunocore Holdings' price analysis, check to measure Immunocore Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunocore Holdings is operating at the current time. Most of Immunocore Holdings' value examination focuses on studying past and present price action to predict the probability of Immunocore Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunocore Holdings' price. Additionally, you may evaluate how the addition of Immunocore Holdings to your portfolios can decrease your overall portfolio volatility.